The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...
As Vertex Pharmaceuticals reels from a painful trial readout for its pain candidate suzetrigine, the Boston biotech has ...
Vertex has won two cystic fibrosis approvals from the FDA, but the agency included high-level safety warnings.
Vertex Pharmaceuticals VRTX announced that the FDA has approved its next-in-class vanza triple therapy for treating people ...
Vertex Pharmaceuticals offers promising opportunities in pain management, cystic fibrosis treatments, and a diversified ...
Vertex Pharmaceuticals Inc. notched two FDA victories late Friday for its cystic fibrosis medicines, increasing the number of ...
The new combination, dubbed Alyftrek, is designed to improve on the Trikafta, a product that generated sales of $8.9 billion ...
According to Vertex Pharmaceuticals, approximately 300 additional people with CF are now eligible to receive treatment.
Despite the real problems with the additional indication being sought for suzetrigine, this drop in the stock is still an ...
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the thirty-one ratings firms that are covering the firm, ...
Everence Capital Management Inc. trimmed its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 5 ...